Immunome (IMNM)
Immunome on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
17.3M
Short interest
settlement 2026-10-15
12.2
Days to cover
+2.3 days vs prior
62.3%
Short share of volume
2026-11-02
2,425
Fails to deliver
settlement 2026-10-08
Thu 5 Nov
Next earnings
estimated date
-$3.5M
Insider flow, 90 days
0 buys, 6 sells
As of 2026-11-02.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in IMNM is 17,281,614 shares, up 1,037,057 shares over the last month. Over the last 48 readings it ranged from 8,800,956 shares (13 December 2024) to 18,945,536 shares (31 March 2026). At the reported average volume of 1.4M shares a day that is 12.2 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/imnm" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 17,281,614 | +3.1% | 1,421,723 | 12.16 |
| 2026-09-30 | 16,757,287 | +3.2% | 1,691,367 | 9.91 |
| 2026-09-15 | 16,244,557 | +3.9% | 787,598 | 20.63 |
| 2026-08-31 | 15,634,596 | -10.1% | 1,236,757 | 12.64 |
| 2026-08-14 | 17,392,529 | -3.3% | 1,165,021 | 14.93 |
| 2026-07-31 | 17,981,724 | +4.3% | 782,638 | 22.98 |
| 2026-07-15 | 17,237,765 | -0.7% | 1,635,317 | 10.54 |
| 2026-06-30 | 17,366,167 | -4.3% | 2,139,319 | 8.12 |
| 2026-06-15 | 18,148,499 | +7.6% | 1,403,494 | 12.93 |
| 2026-05-29 | 16,863,159 | -4.3% | 1,190,675 | 14.16 |
| 2026-05-15 | 17,630,541 | -5.5% | 878,987 | 20.06 |
| 2026-04-30 | 18,658,002 | +0.3% | 824,019 | 22.64 |
| 2026-04-15 | 18,604,286 | -1.8% | 1,118,328 | 16.64 |
| 2026-03-31 | 18,945,536 | +5.9% | 1,792,487 | 10.57 |
| 2026-03-13 | 17,886,375 | -0.0% | 1,213,796 | 14.74 |
| 2026-02-27 | 17,887,518 | +11.5% | 756,553 | 23.64 |
| 2026-02-13 | 16,043,749 | +1.7% | 1,301,804 | 12.32 |
| 2026-01-30 | 15,769,152 | +3.0% | 1,743,024 | 9.05 |
| 2026-01-15 | 15,314,650 | -12.7% | 2,451,335 | 6.25 |
| 2025-12-31 | 17,532,234 | +10.4% | 3,408,543 | 5.14 |
| 2025-12-15 | 15,876,802 | +4.0% | 2,159,764 | 7.35 |
| 2025-11-28 | 15,269,901 | +6.6% | 1,058,799 | 14.42 |
| 2025-11-14 | 14,324,512 | -5.1% | 1,705,325 | 8.40 |
| 2025-10-31 | 15,092,876 | -0.9% | 1,031,149 | 14.64 |
| 2025-10-15 | 15,236,576 | -1.5% | 1,506,287 | 10.12 |
| 2025-09-30 | 15,469,351 | +3.3% | 2,091,749 | 7.40 |
| 2025-09-15 | 14,973,353 | +10.4% | 1,478,902 | 10.12 |
| 2025-08-29 | 13,564,861 | -1.4% | 618,255 | 21.94 |
| 2025-08-15 | 13,763,815 | -3.2% | 664,500 | 20.71 |
| 2025-07-31 | 14,213,917 | +0.1% | 834,505 | 17.03 |
| 2025-07-15 | 14,195,327 | +12.8% | 1,012,394 | 14.02 |
| 2025-06-30 | 12,580,117 | +0.5% | 1,222,425 | 10.29 |
| 2025-06-13 | 12,517,420 | -5.5% | 805,310 | 15.54 |
| 2025-05-30 | 13,239,384 | +4.1% | 877,723 | 15.08 |
| 2025-05-15 | 12,720,847 | -6.8% | 1,018,171 | 12.49 |
| 2025-04-30 | 13,646,456 | +9.3% | 1,083,182 | 12.60 |
| 2025-04-15 | 12,481,987 | +12.1% | 1,251,385 | 9.97 |
| 2025-03-31 | 11,132,992 | +16.9% | 1,811,139 | 6.15 |
| 2025-03-14 | 9,523,078 | +2.4% | 669,043 | 14.23 |
| 2025-02-28 | 9,302,077 | -0.5% | 714,942 | 13.01 |
| 2025-02-14 | 9,350,699 | +3.1% | 1,060,561 | 8.82 |
| 2025-01-31 | 9,069,818 | -14.0% | 1,278,326 | 7.10 |
| 2025-01-15 | 10,544,273 | +6.8% | 620,998 | 16.98 |
| 2024-12-31 | 9,873,217 | +12.2% | 1,004,967 | 9.82 |
| 2024-12-13 | 8,800,956 | -10.1% | 689,172 | 12.77 |
| 2024-11-29 | 9,785,623 | -8.3% | 1,124,412 | 8.70 |
| 2024-11-15 | 10,670,039 | +1.9% | 859,208 | 12.42 |
| 2024-10-31 | 10,468,711 | -4.2% | 470,017 | 22.27 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 2 November 2026, the short share of IMNM volume is 62.3%, down 17.8 points over the last five sessions. Over the last 30 readings it ranged from 45.5% (20 October 2026) to 82.1% (12 October 2026). The latest reading is 3.6 points below the 30-session average of 65.9%, on 927K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-02 | 577K | 927K | 62.3% | 0 |
| 2026-10-30 | 185K | 313K | 59.2% | 0 |
| 2026-10-29 | 197K | 320K | 61.6% | 49 |
| 2026-10-28 | 215K | 342K | 62.9% | 0 |
| 2026-10-27 | 274K | 460K | 59.5% | 7,379 |
| 2026-10-26 | 240K | 299K | 80.1% | 0 |
| 2026-10-23 | 264K | 396K | 66.5% | 0 |
| 2026-10-22 | 289K | 511K | 56.6% | 1,322 |
| 2026-10-21 | 387K | 611K | 63.3% | 0 |
| 2026-10-20 | 416K | 914K | 45.5% | 586 |
| 2026-10-19 | 203K | 342K | 59.4% | 0 |
| 2026-10-16 | 275K | 430K | 64.1% | 0 |
| 2026-10-15 | 240K | 437K | 55.0% | 0 |
| 2026-10-14 | 275K | 359K | 76.7% | 0 |
| 2026-10-13 | 415K | 851K | 48.8% | 900 |
| 2026-10-12 | 243K | 296K | 82.1% | 0 |
| 2026-10-09 | 230K | 291K | 79.0% | 0 |
| 2026-10-08 | 446K | 553K | 80.5% | 0 |
| 2026-10-07 | 212K | 346K | 61.1% | 2,052 |
| 2026-10-06 | 668K | 933K | 71.6% | 6,146 |
| 2026-10-05 | 199K | 338K | 59.0% | 0 |
| 2026-10-02 | 389K | 482K | 80.9% | 0 |
| 2026-10-01 | 258K | 374K | 69.0% | 0 |
| 2026-09-30 | 236K | 324K | 73.0% | 0 |
| 2026-09-29 | 183K | 273K | 67.0% | 0 |
| 2026-09-28 | 167K | 234K | 71.0% | 0 |
| 2026-09-25 | 749K | 1.0M | 73.1% | 144 |
| 2026-09-24 | 725K | 1.1M | 64.1% | 1,693 |
| 2026-09-23 | 447K | 913K | 49.0% | 11 |
| 2026-09-22 | 322K | 421K | 76.4% | 0 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 8 October 2026, the fails-to-deliver balance in IMNM is 2,425 shares, down 27,795 shares over the last settlement date. Over the last 30 readings it ranged from 4 shares (23 July 2026) to 323,575 shares (24 June 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-10-08 | 2,425 | $19.10 | $46K |
| 2026-10-07 | 30,220 | $19.31 | $584K |
| 2026-10-01 | 4,069 | $21.51 | $88K |
| 2026-09-30 | 4,100 | $21.89 | $90K |
| 2026-09-22 | 37 | $25.07 | $928 |
| 2026-09-18 | 107 | $23.93 | $3K |
| 2026-09-11 | 4,036 | $24.97 | $101K |
| 2026-08-25 | 1,036 | $28.01 | $29K |
| 2026-08-24 | 30 | $28.52 | $856 |
| 2026-08-17 | 3,177 | $27.20 | $86K |
| 2026-08-11 | 7 | $25.69 | $180 |
| 2026-08-07 | 66 | $25.82 | $2K |
| 2026-08-06 | 10,582 | $25.52 | $270K |
| 2026-08-03 | 70 | $22.76 | $2K |
| 2026-07-31 | 347 | $23.08 | $8K |
| 2026-07-27 | 522 | $22.21 | $12K |
| 2026-07-23 | 4 | $22.88 | $92 |
| 2026-07-22 | 265 | $22.78 | $6K |
| 2026-07-20 | 993 | $22.32 | $22K |
| 2026-07-09 | 4,107 | $24.01 | $99K |
| 2026-07-06 | 794 | $23.61 | $19K |
| 2026-07-01 | 376 | $21.19 | $8K |
| 2026-06-30 | 7,085 | $21.04 | $149K |
| 2026-06-29 | 6,047 | $19.96 | $121K |
| 2026-06-26 | 209,999 | $19.40 | $4.1M |
| 2026-06-24 | 323,575 | $19.33 | $6.3M |
| 2026-06-18 | 68 | $18.53 | $1K |
| 2026-06-15 | 26,873 | $18.38 | $494K |
| 2026-06-11 | 999 | $18.16 | $18K |
| 2026-06-10 | 199 | $18.39 | $4K |
Insider trades
SEC Form 4, newest first. JSONInsiders at IMNM reported 6 open-market sells worth $3.5M in the last 90 days and no open-market buys. Latest filing: Higgins Jack (Chief Scientific Officer) on 2026-09-11.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-09-11 | Higgins Jack | Chief Scientific Officer | Gift | 9K | $0.00 | $0 | 56K |
| 2026-09-11 | Higgins Jack | Chief Scientific Officer | Sell | 13K | $25.32 | $334K | 65K |
| 2026-09-11 | Higgins Jack | Chief Scientific Officer | Exercise or conversion | 18K | $1.35 | $24K | 78K |
| 2026-08-12 | Barchas Isaac | Director | Sell | 11K | $27.25 | $301K | 92K |
| 2026-08-11 | Barchas Isaac | Director | Sell | 62K | $26.23 | $1.6M | 0 |
| 2026-08-10 | Barchas Isaac | Director | Sell | 10K | $26.07 | $264K | 62K |
| 2026-08-07 | Barchas Isaac | Director | Sell | 15K | $26.06 | $397K | 72K |
| 2026-08-06 | Barchas Isaac | Director | Sell | 21K | $26.06 | $543K | 88K |
| 2026-08-04 | Horn Kinney | CHIEF BUSINESS OFFICER | Sell | 91K | $25.09 | $2.3M | 0 |
| 2026-08-04 | Horn Kinney | CHIEF BUSINESS OFFICER | Exercise or conversion | 40K | $10.60 | $427K | 91K |
| 2026-08-04 | Horn Kinney | CHIEF BUSINESS OFFICER | Exercise or conversion | 50K | $12.92 | $651K | 50K |
| 2026-07-23 | Tsai Philip | Chief Technical Officer | Grant | 38K | $0.00 | $0 | 82K |
| 2026-07-23 | Lechleider Robert | Chief Medical Officer | Grant | 54K | $0.00 | $0 | 70K |
| 2026-07-23 | Rosett Max | Chief Financial Officer | Grant | 47K | $0.00 | $0 | 101K |
| 2026-07-23 | Stoneman Sandra G. | CHIEF LEGAL OFFICER & GC | Grant | 38K | $0.00 | $0 | 44K |
| 2026-07-23 | SIEGALL CLAY B | President and CEO | Grant | 180K | $0.00 | $0 | 871K |
| 2026-07-23 | Horn Kinney | CHIEF BUSINESS OFFICER | Grant | 31K | $0.00 | $0 | 31K |
| 2026-07-23 | Higgins Jack | Chief Scientific Officer | Grant | 38K | $0.00 | $0 | 60K |
| 2026-07-07 | Horn Kinney | CHIEF BUSINESS OFFICER | Sell | 1K | $25.00 | $27K | 0 |
| 2026-07-07 | Horn Kinney | CHIEF BUSINESS OFFICER | Exercise or conversion | 1K | $12.92 | $14K | 1K |
| 2026-07-07 | Barchas Isaac | Director | Sell | 17K | $24.20 | $409K | 109K |
| 2026-07-06 | Barchas Isaac | Director | Sell | 83K | $24.11 | $2.0M | 125K |
| 2026-07-02 | Barchas Isaac | Director | Sell | 24K | $23.33 | $568K | 209K |
| 2026-07-02 | Barchas Isaac | Director | Sell | 76K | $22.35 | $1.7M | 233K |
| 2026-07-02 | Lechleider Robert | Chief Medical Officer | Sell | 16K | $23.44 | $377K | 16K |
| 2026-07-02 | Lechleider Robert | Chief Medical Officer | Sell | 16K | $22.76 | $369K | 32K |
| 2026-07-02 | Lechleider Robert | Chief Medical Officer | Sell | 23K | $21.95 | $499K | 48K |
| 2026-07-02 | Lechleider Robert | Chief Medical Officer | Exercise or conversion | 55K | $8.73 | $480K | 71K |
| 2026-06-30 | Barchas Isaac | Director | Sell | 101K | $21.12 | $2.1M | 309K |
| 2026-06-25 | Lechleider Robert | Chief Medical Officer | Sell | 14K | $20.66 | $298K | 16K |
| 2026-06-25 | Lechleider Robert | Chief Medical Officer | Exercise or conversion | 55K | $8.73 | $480K | 71K |
| 2026-06-25 | Lechleider Robert | Chief Medical Officer | Sell | 41K | $19.56 | $794K | 30K |
| 2026-06-15 | Rosett Max | Chief Financial Officer | Exercise or conversion | 60K | $1.05 | $63K | 114K |
| 2026-06-15 | Rosett Max | Chief Financial Officer | Sell | 60K | $18.23 | $1.1M | 54K |
| 2026-06-05 | BIENAIME JEAN JACQUES | Director | Buy | 1K | $19.27 | $19K | 43K |
| 2026-06-05 | BIENAIME JEAN JACQUES | Director | Buy | 4K | $19.46 | $68K | 42K |
| 2026-06-05 | BIENAIME JEAN JACQUES | Director | Buy | 6K | $19.48 | $117K | 39K |
| 2026-06-05 | BIENAIME JEAN JACQUES | Director | Sell | 10K | $19.41 | $194K | 33K |
| 2026-06-05 | BIENAIME JEAN JACQUES | Director | Sell | 500 | $19.44 | $10K | 43K |
| 2026-05-15 | BIENAIME JEAN JACQUES | Director | Buy | 5K | $20.70 | $104K | 43K |
| 2026-04-02 | Rosett Max | Chief Financial Officer | Sell | 1K | $22.48 | $30K | 54K |
| 2026-04-02 | Rosett Max | Chief Financial Officer | Sell | 64K | $21.91 | $1.4M | 55K |
| 2026-04-02 | Rosett Max | Chief Financial Officer | Exercise or conversion | 40K | $1.35 | $54K | 119K |
| 2026-04-02 | Rosett Max | Chief Financial Officer | Exercise or conversion | 32K | $1.05 | $33K | 79K |
| 2026-04-02 | Higgins Jack | Chief Scientific Officer | Sell | 9K | $21.64 | $204K | 22K |
| 2026-03-30 | Higgins Jack | Chief Scientific Officer | Gift | 6K | $0.00 | $0 | 31K |
| 2026-03-27 | SIEGALL CLAY B | President and CEO | Buy | 25K | $19.67 | $501K | 691K |
| 2026-03-23 | WAGENHEIM PHILIP | Director | Sell | 28K | $20.65 | $582K | 341K |
| 2026-03-20 | WAGENHEIM PHILIP | Director | Sell | 37K | $20.47 | $753K | 369K |
| 2026-03-11 | BIENAIME JEAN JACQUES | Director | Buy | 1K | $21.55 | $22K | 38K |
| 2026-03-10 | BIENAIME JEAN JACQUES | Director | Buy | 1K | $22.12 | $22K | 37K |
| 2025-12-30 | SIEGALL CLAY B | President and CEO | Buy | 5K | $21.15 | $100K | 665K |
| 2025-12-22 | Barchas Isaac | Director | Sell | 11K | $22.34 | $251K | 2.0M |
| 2025-12-22 | Barchas Isaac | Director | Sell | 372K | $21.72 | $8.1M | 2.0M |
| 2025-12-19 | Higgins Jack | Chief Scientific Officer | Gift | 1K | $0.00 | $0 | 1K |
| 2025-12-19 | Higgins Jack | Chief Scientific Officer | Gift | 1K | $0.00 | $0 | 38K |
| 2025-12-19 | Higgins Jack | Chief Scientific Officer | Gift | 1K | $0.00 | $0 | 1K |
| 2025-12-19 | Higgins Jack | Chief Scientific Officer | Gift | 1K | $0.00 | $0 | 39K |
| 2025-12-19 | Higgins Jack | Chief Scientific Officer | Gift | 1K | $0.00 | $0 | 1K |
| 2025-12-19 | Tsai Philip | Chief Technical Officer | Buy | 10K | $20.49 | $205K | 43K |
| 2025-12-19 | SIEGALL CLAY B | President and CEO | Gift | 200K | $0.00 | $0 | 661K |
| 2025-12-19 | SIEGALL CLAY B | President and CEO | Buy | 7K | $20.48 | $149K | 861K |
| 2025-12-19 | Higgins Jack | Chief Scientific Officer | Gift | 1K | $0.00 | $0 | 40K |
| 2025-12-18 | SIEGALL CLAY B | President and CEO | Buy | 47K | $21.50 | $1000K | 853K |
| 2025-09-10 | Higgins Jack | Chief Scientific Officer | Exercise or conversion | 22K | $1.35 | $30K | 41K |
| 2025-06-03 | BIENAIME JEAN JACQUES | Director | Buy | 5K | $9.38 | $47K | 36K |
| 2025-03-27 | Higgins Jack | Chief Scientific Officer | Exercise or conversion | 5K | $1.35 | $7K | 19K |
| 2025-03-26 | SIEGALL CLAY B | President and CEO | Buy | 137K | $7.29 | $999K | 807K |
| 2025-03-25 | BIENAIME JEAN JACQUES | Director | Buy | 8K | $7.78 | $61K | 31K |
| 2025-03-24 | Tsai Philip | Chief Technology Officer | Buy | 12K | $8.42 | $104K | 33K |
| 2025-03-24 | BIENAIME JEAN JACQUES | Director | Buy | 7K | $8.21 | $57K | 24K |
| 2025-01-31 | SIEGALL CLAY B | President and CEO | Buy | 150K | $7.75 | $1.2M | 670K |
| 2024-11-22 | SIEGALL CLAY B | President and CEO | Buy | 34K | $9.78 | $332K | 520K |
| 2024-11-21 | Tsai Philip | Chief Technology Officer | Buy | 21K | $9.43 | $198K | 21K |
| 2024-11-21 | Lechleider Robert | Chief Medical Officer | Buy | 16K | $9.48 | $150K | 16K |
| 2024-11-21 | SIEGALL CLAY B | President and CEO | Buy | 66K | $9.54 | $630K | 486K |
| 2024-09-19 | Rosett Max | Chief Financial Officer | Exercise or conversion | 42K | $1.05 | $44K | 62K |
| 2024-09-19 | Rosett Max | Chief Financial Officer | Sell | 14K | $16.01 | $230K | 47K |
| 2024-08-19 | Higgins Jack | Chief Scientific Officer | Gift | 2K | $0.00 | $0 | 14K |
| 2024-08-16 | BIENAIME JEAN JACQUES | Director | Buy | 7K | $13.94 | $98K | 17K |
| 2024-08-15 | Higgins Jack | Chief Scientific Officer | Exercise or conversion | 20K | $1.35 | $26K | 20K |
| 2024-08-15 | Higgins Jack | Chief Scientific Officer | Sell | 4K | $13.93 | $49K | 16K |
| 2024-05-21 | SIEGALL CLAY B | President and CEO | Buy | 20K | $13.78 | $282K | 420K |
| 2024-05-21 | BIENAIME JEAN JACQUES | Director | Buy | 2K | $13.57 | $27K | 10K |
| 2024-05-20 | SIEGALL CLAY B | President and CEO | Buy | 80K | $13.91 | $1.1M | 399K |
| 2023-10-02 | RAPP MICHAEL | Director | Grant | 254K | $5.91 | $1.5M | 1.1M |
| 2023-10-02 | PRENDERGAST FRANKLYN G | Director | Grant | 61K | $0.00 | $0 | 61K |
| 2023-10-02 | Turner Bruce | Chief Strategy Officer | Buy | 42K | $5.91 | $250K | 42K |
| 2023-10-02 | SIEGALL CLAY B | President and CEO | Buy | 169K | $5.91 | $1000K | 320K |
| 2023-01-15 | RAPP MICHAEL | Director | Grant | 18K | $4.00 | $70K | 817K |
| 2023-01-15 | Lefenfeld Michael | Director | Grant | 14K | $4.00 | $56K | 41K |
| 2023-01-15 | LAMATTINA JOHN L | Director | Grant | 15K | $4.00 | $61K | 67K |
| 2023-01-15 | WAGENHEIM PHILIP | Director | Grant | 9K | $4.00 | $35K | 406K |
| 2021-09-13 | RAPP MICHAEL | Director | Buy | 26K | $19.96 | $518K | 209K |
| 2021-09-10 | RAPP MICHAEL | Director | Buy | 16K | $17.85 | $277K | 183K |
| 2021-09-09 | RAPP MICHAEL | Director | Buy | 8K | $17.44 | $142K | 145K |
| 2021-09-09 | RAPP MICHAEL | Director | Buy | 22K | $18.46 | $411K | 167K |
| 2021-08-18 | BARON RICHARD A | Director | Exercise or conversion | 2K | $11.38 | $27K | 2K |
| 2021-05-26 | RAPP MICHAEL | Director | Buy | 2K | $18.94 | $44K | 137K |
| 2021-05-26 | Lefenfeld Michael | Director | Buy | 1K | $19.03 | $25K | 27K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON11 Form 144 notices on file for IMNM worth $14.0M at the prices reported; 2 in the last 90 days worth $635K. Latest: Higgins Jack filed on 2026-09-11 to sell 13,200 shares ($334K) from 2026-09-11.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-09-11 | Higgins JackOfficer | 13K | $334K | 0.012% | 2026-09-11 | Fidelity Brokerage Services LLC |
| 2026-08-12 | Barchas IsaacDirector | 11K | $301K | 0.010% | 2026-08-12 | Fidelity Brokerage Services LLC |
| 2026-08-04 | Horn KinneyOfficer | 91K | $2.3M | 0.080% | 2026-08-04 | Fidelity Brokerage Services LLC |
| 2026-07-07 | Horn KinneyOfficer | 1K | $27K | 0.001% | 2026-07-07 | Fidelity Brokerage Services LLC |
| 2026-07-02 | Lechleider RobertOfficer | 55K | $1.2M | 0.049% | 2026-07-02 | Fidelity Brokerage Services LLC |
| 2026-06-25 | Lechleider RobertOfficer | 55K | $1.1M | 0.049% | 2026-06-25 | Fidelity Brokerage Services LLC |
| 2026-06-15 | Rosett MaxOfficer | 60K | $1.1M | 0.053% | 2026-06-15 | Fidelity Brokerage Services LLC |
| 2026-04-03 | Rosett MaxOfficer | 65K | $1.4M | 0.057% | 2026-04-02 | Fidelity Brokerage Services LLC |
| 2026-04-02 | Rosett MaxOfficer | 65K | $4.7M | 0.057% | 2026-04-02 | Fidelity Brokerage Services LLC |
| 2026-04-02 | Higgins JackOfficer | 9K | $204K | 0.008% | 2026-04-02 | Fidelity Brokerage Services LLC |
| 2026-03-20 | WAGENHEIM PHILIPDirector | 65K | $1.4M | 0.071% | 2026-03-20 | RBC CAPITAL MARKETS LLC |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON4 holders report 5% or more of IMNM in their latest filing, all on Schedule 13G (passive). The largest reported stake is T. Rowe Price Investment Management, Inc. at 17.4% of the class (19,676,883 shares), filed 2026-08-14 for an event on 2026-06-30.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-10-30 | 13G | Vanguard Capital Managementinvestment adviser | 5.7M | 5.0% | 2026-09-30 |
| 2026-08-14 | 13G/Ano. 2 | T. Rowe Price Investment Management, Inc.investment adviser | 19.7M | 17.4% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | Sirenia Capital Management LPinvestment adviser, partnership | 4.8M | 4.3% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | Alex Silversteinparent holding company, individual | 4.8M | 4.3% | 2026-06-30 |
| 2026-05-15 | 13G/Ano. 4 | Jeremy C. Greenparent holding company, individual | 5.6M | 4.9% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 4 | Redmile Group, LLCinvestment adviser, other entity | 5.6M | 4.9% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 1 | Point72 Asset Management, L.P.partnership | 0 | 0.0% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 1 | Steven A. Cohenindividual | 0 | 0.0% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 1 | Point72 Capital Advisors, Inc.corporation | 0 | 0.0% | 2026-03-31 |
| 2026-03-26 | 13G/Ano. 3 | The Vanguard Groupinvestment adviser | 0 | 0.0% | 2026-03-13 |
| 2025-12-22 | 13D/Ano. 2 | Enavate Sciences GP, LLCother entity | 4.8M | 4.3% | 2025-12-18 |
| 2025-12-22 | 13D/Ano. 2 | Immunome Aggregator, LPpartnership | 4.8M | 4.3% | 2025-12-18 |
| 2025-10-07 | 13G/Ano. 1 | FMR LLCparent holding company | 13.1M | 15.0% | 2025-09-30 |
| 2025-10-07 | 13G/Ano. 1 | Abigail P. Johnsonindividual | 13.1M | 15.0% | 2025-09-30 |
13F holders
Tracked managers holding IMNM at their latest 13F. JSON4 of the 30 tracked managers held IMNM at their latest 13F, $10.8M in total at quarter-end prices. Renaissance Technologies is the largest at $5.3M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 3 added shares and 1 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Renaissance Technologies | 2026-06-30 | 251K | $5.3M | 0.01% | +182K |
| Citadel Advisors | 2026-06-30 | 224K | $4.7M | 0.00% | +144K |
| Two Sigma Investments | 2026-06-30 | 24K | $507K | 0.00% | new |
| AQR Capital Management | 2026-06-30 | 12K | $250K | 0.00% | -7K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
What this page is
Immunome in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Immunome (IMNM), SEC CIK 1472012, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-08.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-09-11.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-10-30.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-11.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-09-11.JSON and CSV
- Company record
- EDGAR filing index for CIK 1472012Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
Other company pages
- STESTERIS
- STLDSteel Dynamics
- STRCStrategy
- STRLSterling Infrastructure
- STTState Street
- STXSeagate Technology Holdings
- STZConstellation Brands
- SUISun Communities
- SUNBSunbelt Rentals Holdings
- SWSmurfit Westrock
- SWKStanley Black & Decker
- SWKSSkyworks Solutions
- SXTCChina SXT Pharmaceuticals
- SYFSynchrony Financial
- SYKStryker
- SYNASynaptics
Datasets
Frequently Asked Questions
How much of IMNM is sold short?
17,281,614 shares were held short at the 2026-10-15 settlement, 12.2 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is IMNM's daily short volume?
On 2026-11-02, 577,325 of the 926,588 IMNM shares reported to FINRA were sold short, 62.3% of the day's reported volume. Short volume is a flow for one day, not a position.
Does IMNM have fails to deliver?
The SEC's latest file shows 2,425 IMNM shares failed to deliver at settlement 2026-10-08. Fails are reported per settlement date and published twice a month with a lag.
Are IMNM insiders buying or selling?
Insiders at IMNM reported 6 open-market sells worth $3.5M in the last 90 days and no open-market buys. Latest filing: Higgins Jack (Chief Scientific Officer) on 2026-09-11.
Have IMNM insiders filed to sell?
11 Form 144 notices on file for IMNM worth $14.0M at the prices reported; 2 in the last 90 days worth $635K. Latest: Higgins Jack filed on 2026-09-11 to sell 13,200 shares ($334K) from 2026-09-11.
Who owns 5% or more of IMNM?
4 holders report 5% or more of IMNM in their latest filing, all on Schedule 13G (passive). The largest reported stake is T. Rowe Price Investment Management, Inc. at 17.4% of the class (19,676,883 shares), filed 2026-08-14 for an event on 2026-06-30.
Which tracked 13F managers own IMNM?
4 of the 30 tracked 13F managers held IMNM shares at their latest filing, $10.8M in all. The largest: Renaissance Technologies (251K shares, $5.3M), Ken Griffin's Citadel Advisors (224K shares, $4.7M), Two Sigma Investments (24K shares, $507K), Cliff Asness's AQR Capital Management (12K shares, $250K).
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.